Table 3. Nissen and Wolski re-analysis for myocardial infarction relative risk for rosiglitazone.

Method	Estimated relative risk RX: control (95% CI)	P-value: two-sided	Ratio of 95% confidence lengths method: Inv Var
Mainstream Weights (RR)	1.28 (0.94, 1.75)	0.12	1.00
Ratio (Survey Sampling) (RR)	1.41 (1.14, 1.75)	0.0026	0.82
Nissen and Wolski (OR)	1.43 (1.03–1.98)	0.032	1.03